Johnson and Johnson seeks approval of single shot vaccine
PROVIDENCE, R.I. (WLNE)- Johnson and Johnson has officially requested an Emergency Use Authorization (EUA) for its single shot vaccine from the U.S. Food and Drug Administration.
The company submitted data collected during Phase 3 of testing, where the vaccine was 66% effective at preventing COVID-19 28 days after vaccination.
According to Thursday’s press release, Johnson and Johnson will have the vaccine ready to ship as soon as it is approved.
“Today’s submission for Emergency Use Authorization of our investigational single-shot COVID-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson.
Stoffels continued to explain the company’s eagerness to have the vaccine approved, “Upon authorization of our investigational COVID-19 vaccine for emergency use, we are ready to begin shipping. With our submission to the FDA and our ongoing reviews with other health authorities around the world, we are working with great urgency to make our investigational vaccine available to the public as quickly as possible.”